Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years

作者：Guerrieri Gonzaga Aliana; Botteri Edoardo; Rotmensz Nicole; Bassi Fabio; Intra Mattia; Serrano Davide; Renne Giuseppe; Luini Alberto; Cazzaniga Massimiliano; Goldhirsch Aaron; Colleoni Marco; Viale Giuseppe; Ivaldi Giovanni; Bagnardi Vincenzo; Lazzeroni Matteo; Decensi Andrea^*; Veronesi Umberto; Bonanni Bernardo

来源：Oncologist, 2009, 14(3): 201-212.

DOI：10.1634/theoncologist.2008-0203

• Intraepithelial neoplasia
• Tamoxifen
• Chemoprevention
• Radiotherapy

Introduction. Diagnosis of breast ductal intraepithelial neoplasia ( DIN) has increased over the last decades, but proper postsurgical treatment remains controversial. We analyzed risk factors and treatment outcome in a large series of women treated at one institution.
Methods. Women undergoing surgery for DIN at the European Institute of Oncology between 1996 and 2005, with follow-up until December 2006, were included.
Results. We evaluated the postsurgical treatment outcome of 974 and 293 patients who underwent breast-conserving surgery (BCS) or mastectomy, respectively. The 5-year cumulative incidence of breast cancer (BC) events was 11.8%, with a significant trend according to age (from 43% in women < 36 years to 8% in women > 65 years).
Among the 727 BCS patients with DIN2-DIN3 histology, 414 (57%) received radiotherapy (RT), and they were both younger and with worse prognostic factors than the 313 patients who did not receive it. In these groups, the adjusted hazard ratio (HR) for RT versus non-RT was 0.40 (95% confidence interval [ CI], 0.26-0.63).
Among the 691 BCS patients with estrogen receptor (ER)(+) disease, 329 (48%) received low-dose tamoxifen (either 5 mg/day or 20 mg once a week) and they were younger than the 362 who did not receive it. In these groups, the adjusted HR for tamoxifen versus no tamoxifen was 0.68 (95% CI, 0.43-1.07), and the HR was 0.55 (95% CI, 0.32-0.97) after excluding human epidermal growth factor receptor (HER)2/neu-overexpressing DIN.
Conclusions. BC events were more frequent in young patients. RT was associated with a lower incidence of BC events. Low-dose tamoxifen was associated with a lower incidence of BC events in patients with ER(+) disease when HER-2 was not overexpressed. Further prospective studies should confirm our observations. The Oncologist 2009; 14: 201-212

• 出版日期2009